The Exeter Activity Unlimited statement on physical activity and exercise for cystic fibrosis: methodology and results of an international, multidisciplinary, evidence-driven expert consensus
Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid
StandardStandard
Yn: Chronic Respiratory Disease, Cyfrol 19, 19.12.2022.
Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid
HarvardHarvard
APA
CBE
MLA
VancouverVancouver
Author
RIS
TY - JOUR
T1 - The Exeter Activity Unlimited statement on physical activity and exercise for cystic fibrosis: methodology and results of an international, multidisciplinary, evidence-driven expert consensus
AU - Williams, Craig A.
AU - Barker, Alan R.
AU - Denford , Sarah
AU - van Beurden, Samantha B
AU - Silveira Bianchim, May
AU - Caterini, Jessica E
AU - Cox, Narelle S.
AU - Mackintosh, Kelly
AU - McNarry, Melitta A.
AU - Rand, Sarah
AU - Schneiderman , Jane
AU - Wells, Greg D
AU - Anderson, Peter
AU - Tomlinson , Owen W
N1 - No date of acceptance
PY - 2022/12/19
Y1 - 2022/12/19
N2 - BackgroundThe roles of physical activity (PA) and exercise within the management of cystic fibrosis (CF) are recognised by their inclusion in numerous standards of care and treatment guidelines. However, information is brief, and both PA and exercise as multi-faceted behaviours require extensive stakeholder input when developing and promoting such guidelines.MethodOn 30th June and 1st July 2021, 39 stakeholders from 11 countries, including researchers, healthcare professionals and patients participated in a virtual conference to agree an evidence-based and informed expert consensus about PA and exercise for people with CF. This consensus presents the agreement across six themes: (i) patient and system centred outcomes, (ii) health benefits, iii) measurement, (iv) prescription, (v) clinical considerations, and (vi) future directions. The consensus was achieved by a stepwise process, involving: (i) written evidence-based synopses; (ii) peer critique of synopses; (iii) oral presentation to consensus group and peer challenge of revised synopses; and (iv) anonymous voting on final proposed synopses for adoption to the consensus statement.ResultsThe final consensus document includes 24 statements which surpassed the consensus threshold (>80% agreement) out of 30 proposed statements.ConclusionThis consensus can be used to support health promotion by relevant stakeholders for people with CF.
AB - BackgroundThe roles of physical activity (PA) and exercise within the management of cystic fibrosis (CF) are recognised by their inclusion in numerous standards of care and treatment guidelines. However, information is brief, and both PA and exercise as multi-faceted behaviours require extensive stakeholder input when developing and promoting such guidelines.MethodOn 30th June and 1st July 2021, 39 stakeholders from 11 countries, including researchers, healthcare professionals and patients participated in a virtual conference to agree an evidence-based and informed expert consensus about PA and exercise for people with CF. This consensus presents the agreement across six themes: (i) patient and system centred outcomes, (ii) health benefits, iii) measurement, (iv) prescription, (v) clinical considerations, and (vi) future directions. The consensus was achieved by a stepwise process, involving: (i) written evidence-based synopses; (ii) peer critique of synopses; (iii) oral presentation to consensus group and peer challenge of revised synopses; and (iv) anonymous voting on final proposed synopses for adoption to the consensus statement.ResultsThe final consensus document includes 24 statements which surpassed the consensus threshold (>80% agreement) out of 30 proposed statements.ConclusionThis consensus can be used to support health promotion by relevant stakeholders for people with CF.
KW - respiratory disease
KW - Lifestyle
KW - Health
KW - clinical practice
U2 - 10.1177/14799731221121670
DO - 10.1177/14799731221121670
M3 - Article
VL - 19
JO - Chronic Respiratory Disease
JF - Chronic Respiratory Disease
SN - 1479-9723
ER -